Cargando…
Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid
High consequence human pathogenic viruses must be handled at biosafety level 2, 3 or 4 and must be rendered non-infectious before they can be utilized for molecular or immunological applications at lower biosafety levels. Here we evaluate psoralen-inactivated Arena-, Bunya-, Corona-, Filo-, Flavi- a...
Autores principales: | Schneider, Katherine, Wronka-Edwards, Loni, Leggett-Embrey, Melissa, Walker, Eric, Sun, Peifang, Ondov, Brian, Wyman, Travis H., Rosovitz, MJ, Bohn, Sherry S., Burans, James, Kochel, Tadeusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664985/ https://www.ncbi.nlm.nih.gov/pubmed/26569291 http://dx.doi.org/10.3390/v7112912 |
Ejemplares similares
-
Limited Effectiveness of Psoralen- and Ultraviolet-Inactivated Vaccinia Virus on SHIV Infection
por: Glenn, L. Lee
Publicado: (2013) -
The Battle between Infection and Host Immune Responses of Dengue Virus and Its Implication in Dengue Disease Pathogenesis
por: Sun, Peifang, et al.
Publicado: (2013) -
Psoralen-ultraviolet A treatment with Psoralen-ultraviolet B therapy in the treatment of psoriasis
por: Ahmed Asim, Sadaf, et al.
Publicado: (2013) -
Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
por: Sundaram, Appavu K., et al.
Publicado: (2021) -
Site-directed gene mutation at mixed sequence targets by psoralen-conjugated pseudo-complementary peptide nucleic acids
por: Kim, Ki-Hyun, et al.
Publicado: (2007)